Flow Cytometry Market Size, Share & Trends Analysis Report By Product (Instruments, Software), By Technology (Bead-based, Cell-based), By Application (Industrial, Clinical), By End-use- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global flow cytometry market size is evaluated at USD 5.59 billion in 2022 and is expected to hit around USD 9.40 billion by 2030, growing at a CAGR of 7.09% from 2022 to 2030. 

Key Takeaways:

  • The instrument product segment held the largest share in 2021 due to technical advancements, as well as increased prevalence of chronic conditions
  • Thecell-based flow cytometry technology dominated the industry in 2021 due to the high demand for early diagnosis and rising awareness about the associated benefits of cell-based assays
  • By application, the clinical segment accounted for the largest revenue share in 2021 owing to increasedR&D activities pertaining to infectious diseases, such as influenza, HIV, and COVID-19, among others
  • The academic institutes end-user segment led the market in 2021 owing to increased R&D activities by academic institutes & research centers
  • North America was theleadingregion in 2021due to the high implementation of scientifically advanced flow cytometry solutions, high healthcare expenditure, and well-established healthcare infrastructure in the region
  • Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 owing to the extensive growth in the pharmaceutical and biotechnology industries in emerging economies, such as China and India

Technological advancements in the technique are introducing new and improved analytical tools, which include the development of microfluidic flow cytometry for Point-of-Care (PoC) testing. Furthermore, the rising prevalence of cancer, immunodeficiency disorders, and infectious diseases is driving the industry. In addition, increasing R&D investments in biopharmaceutical, life science, and biotechnology research activities have led to high demand for flow cytometry instruments.In recent years, a key focus has been on the development of portable microfluidic flow cytometry devices for PoC testing.

Microfluidics and flow cytometry together make a useful tool to measure multiple characteristics of biological samples. For instance, the easy availability of several microfluidics and miniaturized detectors have enabled the creation of microchip-based cytometers, such as optofluidic cytometer, imaging cytometer, and impedance cytometer. The development of microfluidic flow cytometry devices, which are cost-effective, portable, and compact, is beneficial. They are affordable in developing economies, such as Asia & Africa, and are enabling rapid growth in PoC testing applications.Furthermore, improvements in fluorescent dyes and the increasing utility of benchtop cytometers for academic research settings are expected to drive the industry.

Developments in multicolor flow cytometry are accelerating the adoption of the technique in novel drug development activities. For instance, in January 2020, DxFLEX, CE-IVD, a 13-colour clinical flow cytometry system was launched by Beckman Coulter Life Sciences in Europe. Similarly, easy cellular analysis by simultaneous evaluation of several parameters allows extensive use of such devices for contract research purposes.The COVID-19 pandemic also spurred innovations in the technique, as evidenced by the launch of new products in this domain. For instance, in July 2021, Metropolis Healthcare Ltd. launched CoviRisk–TBNK, a simple blood test to detect the risk status of a COVID-19 hospitalized patient.

It helps analyze patients’ need for ICU facilities or ventilation and aids in the reduction of stress on healthcare resources. The test is a flow cytometry-based lymphocyte subset assay and is IVD-approved. Such innovations are anticipated to fuel industry growth in the near future.Moreover, flow cytometry is a significant tool in listing and characterizing immune cells, and is also helpful in recognizing and validating underlying genetic defects. The technique is also used to observe and monitor the immune response of patients after stem cell transplantation, and hence, organ transplantation plays an important role in boosting industry growth. According to the WHO, around 50,000 stem cell transplantations are performed globally every year, and this number is expected to grow in the near future, broadening the scope of applications for the technique.

On the other hand, instruments are highly expensive, and hence, buyers in several developing countries may not be able to afford technologically advanced flow cytometry equipment. These instruments may cost over USD 100,000 and pose significant budgetary constraints for small- & mid-sized hospitals and clinical laboratories. However, some manufacturers, such as Sony, are trying to launch newer instruments using software to automate a number of processes. Such developments would not only improve the usability of the technique but also help bring down the average instrumentation cost–under USD 100,000–in the near future.

Report Scope of the Flow Cytometry Market

Report Coverage

Details

Market Size

USD 9.40 Billion by 2030

Growth Rate

CAGR of 7.09% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Product, technology, application, end-use and Region,

Companies Mentioned

Danaher Corp.; Becton, Dickinson and Company (BD);Sysmex Corp.; Agilent Technologies, Inc.; Apogee Flow Systems Ltd.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Stratedigm, Inc.; DiaSorin S.p.A.; Miltenyi Biotec; Sony Biotechnology, Inc.

 

Product Insights

The instrument segment dominated the global industry in 2021 and accounted for the largest share of more than 35.40% owing to the higher penetration coupled with technological advancements. In January 2022, Sony Biotechnology, Inc. introduced its CGX10, a new closed-cell isolation system for use in GMP-compliant cell sorting applications. The initiative was expected to open new growth opportunities for the company. Such advancements in technology result in cost-effectiveness, enhanced accuracy, & portability and are likely to create future growth opportunities.

Small-sized high-throughput cytometers are likely to gain acceptance in the coming years. This is due to allied advantages, such as user-friendliness and cost-effectiveness. The software segment is expected to witness a significant growth rate during the forecast years. The software in flow cytometry is used to control & acquire data generated by cytometers, analyze the information, and provide statistical analysis of the outcomes. For research purposes, the software is used for cell acquisition & data analysis, while in clinical diagnosis, it is used for disease diagnosis by analyzing patients’ samples.

Such wide applications are projected to boost the industry in near future. Moreover, new product developments by key companies are among other significant factors driving the segment growth. For instance, in September 2022, BD announced the launch of a BD software solution specifically designed for flow cytometry workflow. This software enables higher-quality experiments with faster time to insight for scientists working in various disciplines such as oncology, virology immunology, and infectious disease monitoring.

Technology Insights

The cell-based flow cytometry technology segment dominated the industry in 2021 and accounted for the maximum share of more than 77.40% of the overall revenue. Increasing awareness about the benefits associated with cell-based assays and rising demand for early diagnosis are factors contributing to its dominance. Furthermore, technological advancements in cell-based assays, such as innovation in software, instruments, algorithms, affinity reagents, and labels, are expected to drive the adoption in the coming years. The bead-based assay segment is estimated to grow at a significant CAGR of more than during the forecast period.

Bead-based flow cytometry is used to measure various intracellular soluble proteins, including growth factors, cytokines, chemokines, and phosphorylated cell signaling proteins. High-throughput flow cytometry technique is considered an optimal tool for conducting multiplex bead-based assays. Multiplex bead-based technique has high growth potential in the field of research, diagnosis, and treatment of infectious diseases. The need for these assays is expected to show lucrative growth in the coming years owing to advancements in monoclonal antibody production and molecular engineering and the accompanying advantages, such as cost-efficiency, short turnaround time, and micro-sampling capabilities.

Application Insights

The clinical segment accounted for the largest share of more than 45.99% in 2021. This high share can be attributed to increasing research & development activities pertaining to cancer and infectious diseases, including COVID-19. Furthermore, rising R&D investments in the biotechnology and pharmaceutical industry are likely to create a conducive environment for market growth. In addition, Furthermore, unceasing growth strategies by key players in the industry and the launch of novel flow cytometry solutions for clinical applications are also anticipated to significantly support segment growth. For instance, in March 2022, Beckman Coulter launched CellMek SPS, which is a powerful solution for data management and manual sample preparation bottlenecks in clinical flow cytometry. The industrial segment is expected to register the fastest CAGR over the forecast period.

This is due to the increasing applications of flow cytometry in cell culture. The technique finds applications in the pharmaceutical industry, such as drug development process including, target identification, drug characteristics & compound screening, non-clinical safety and toxicity evaluation, and clinical research. Flow cytometry offers a high throughput and rapidity for large-scale drug development and testing detects multiple parameters on the cell surface, coupled with data analysis generates complex and sufficient data by excluding false positives in single-parameter tests. The associated advantages of using flow cytometry in large-scale bioprocessing operations for drug development are expected to fuel market growth over the forecast period.

End-use Insights

The academic institutes segment accounted for the highest revenue share of more than the market in 2021. The technique is used in cell biology & molecular diagnostic studies to measure cell parameters such as the physical properties of cells and recognition of biomarkers through specific antibodies, cell type, cell lineage, and maturation stage. This technology has applications in several educational fields, including molecular biology, immunology, pathology, plant biology, and marine biology. With rising R&D activities, the segment is expected to exhibit significant growth during the forecast period.

The clinical testing labs segment is anticipated to register the fastest CAGR from 2022 to 2030. This is due to the growing need for cost-effective diagnosis of target diseases, such as cancer.It is a widely used tool in the diagnosis and treatment of cancers and immunodeficiency diseases. The rising prevalence of cancer and chronic diseases has resulted in a high demand for diagnostic tests, which is expected to drive the demand for the technique in clinical testing laboratories over the forecast period.

Regional Insights

North America dominated the overall industry and accounted for the largest share of more than 40.90% of the revenue in 2021. This dominance is due to the high implementation of scientifically advanced flow cytometry solutions, high healthcare expenditure, and well-established healthcare infrastructure in the U.S. In addition, widespread research activities by research universities and the presence of established pharmaceutical companies have generated a huge demand for flow cytometry workflow for research needs. In addition, the high prevalence of infectious and chronic diseases, including the outbreak of COVID-19, has led to an increase in the demand for the technique for research and diagnosis purposes.

Asia Pacific is anticipated to witness significant growth as a result of the growing pharmaceutical and biotechnology industries in emerging economies, such as China and India. The industry is driven by the growing incidence of chronic diseases and the increasing use of cytometry devices in various applications in the region. Moreover, ongoing innovations in the fields of cancer & infectious illnesses, such as COVID-19, are expected to drive the regional market. In addition, extensive research activities by regional players for the improvement or development of innovative flow cytometry solutions are expected to support market growth in the region over the projected period.

Some of the prominent players in the Flow Cytometry Market include:

  • Danaher Corp.
  • Becton, Dickinson, and Company (BD)
  • Sysmex Corp.
  • Agilent Technologies, Inc.
  • Apogee Flow Systems Ltd.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Stratedigm, Inc.
  • DiaSorin SpA
  • Miltenyi Biotec
  • Sony Biotechnology, Inc.

 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Flow Cytometry market

  • Product
    • Instruments
      • Cell Analyzers
      • Cell Sorters
    • Reagents & Consumables
    • Software
    • Accessories
    • Services
  • Technology
    • Cell-based
    • Bead-based
  • Application
    • Research
      • Pharmaceutical
        • Drug Discovery
        • Stem Cell
        • In Vitro Toxicity
      • Apoptosis
      • Cell Sorting
      • Cell Cycle Analysis
      • Immunology
      • Cell Viability
    • Industrial
    • Clinical
      • Cancer
      • Organ Transplantation
      • Immunodeficiency
      • Hematology
  • End-use
    • Commercial Organizations
      • Biotechnology Companies
      • Pharmaceutical Companies
      • CROs
    • Hospitals
    • Academic Institutes
    • Clinical Testing Labs

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Flow Cytometry industry analysis from 2022 to 2030 to identify the prevailing Flow Cytometry industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Flow Cytometry industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Flow Cytometry industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7550
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000